1382465-53-3

Upstream product

• 1330752-58-3 tert-butyl N-(2-cyclopropyl-2-oxo-ethyl)carbamate 
• 1373754-96-1 5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinic acid 

Downstream Products

• 1382465-67-9 N-{2-cyclopropyl-2-[(Z)-2,2,2-trifluoro-ethoxyimino]-ethyl}-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 
• 1382465-35-1 N-{2-cyclopropyl-2-[(E)-2,2,2-trifluoro-ethoxyimino]-ethyl}-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 
• 1382465-24-8 N-(E)-(2-cyclopropyl-2-hydroxyimino-ethyl)-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 

Relevant academic research and scientific papers

OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS

The present invention relates to compounds of the formula (I) wherein A1 to A3 and R1 to R9 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

OXIME COMPOUNDS

The present invention relates to compounds of the formula wherein A1 to A3 and R1 to R9 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.